MedTrace Logo

Gene Therapy for Wet AMD

NCT05611424 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2023-04-26

No results posted yet for this study

Summary

FT-003 is a gene therapy product developed for the treatment of neovascular age-related macular degeneration (nAMD). Neovascular AMD is the main cause of blindness among elderly individuals. The available therapies for treating nAMD require life-long intravitreal (IVT) injections every 4-12 weeks to maintain efficacy. Administration of FT-003 has the potential to treat nAMD by providing durable expression of therapeutic levels of intraocular protein and maintaining the vision of patients. FT-003 is designed to reduce the current treatment burden which often results in undertreatment and vision loss in patients with nAMD receiving anti-VEGF therapy in clinical practice.

Conditions

  • Neovascular Age-related Macular Degeneration

Interventions

GENETIC

FT-003

Administered via intraocular injection.

Sponsors & Collaborators

  • The First Affiliated Hospital of Soochow University

    collaborator OTHER

  • Tianjin Medical University Eye Hospital

    collaborator OTHER

  • Peking Union Medical College Hospital

    collaborator OTHER

  • The First Affiliated Hospital of Zhengzhou University

    collaborator OTHER

  • Frontera Therapeutics

    lead INDUSTRY

Principal Investigators

  • Peirong Lu, Professor · The First Affiliated Hospital of Soochou University

  • Xiaorong Li, Professor · Tianjin Medical University Eye Hospital

  • Hanyi Min · Peking Union Medical College Hospital

  • Guangming Wan · The First Affiliated Hospital of Zhengzhou University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-01
Primary Completion
2024-11-30
Completion
2027-12-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05611424 on ClinicalTrials.gov